Progyny, Inc. (NASDAQ:PGNY) Receives $25.30 Consensus Price Target from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $25.30.

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. JPMorgan Chase & Co. increased their target price on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Leerink Partnrs upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Truist Financial raised their price objective on shares of Progyny from $24.00 to $27.00 and gave the company a “hold” rating in a research report on Thursday, July 17th. Finally, Leerink Partners upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price objective for the company in a research report on Tuesday, July 8th.

Progyny Stock Down 1.7%

PGNY opened at $22.13 on Thursday. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 1.84 and a beta of 1.33. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76. The company’s 50-day moving average price is $23.07 and its two-hundred day moving average price is $22.21.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.Progyny’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, sell-side analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the transaction, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,895 shares of company stock valued at $179,311 over the last 90 days. 9.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Progyny

A number of large investors have recently modified their holdings of the company. State of Wyoming boosted its position in shares of Progyny by 368.8% in the second quarter. State of Wyoming now owns 22,793 shares of the company’s stock valued at $501,000 after acquiring an additional 17,931 shares during the period. Nomura Holdings Inc. purchased a new stake in Progyny in the second quarter valued at approximately $9,368,000. Public Sector Pension Investment Board raised its stake in Progyny by 8.2% in the second quarter. Public Sector Pension Investment Board now owns 254,208 shares of the company’s stock valued at $5,593,000 after purchasing an additional 19,240 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Progyny by 203.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after purchasing an additional 4,708 shares in the last quarter. Finally, State of Tennessee Department of Treasury raised its stake in Progyny by 26.0% in the second quarter. State of Tennessee Department of Treasury now owns 49,150 shares of the company’s stock valued at $1,081,000 after purchasing an additional 10,150 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.